A Registry Study to Evaluate Outcomes of PEMF Therapy in Subjects With Various Pain Etiologies

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-31

Study Completion Date

2017-12-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is an open-label, non-controlled study of the safety and effectiveness of investigator determined Provant therapy in subjects with pain and/or edema from various pain etiologies. Information collected in the study will be entered into a registry database.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of PEMF (Pulsed Electromagnetic Field) Therapy in the Treatment of Persistent Post-Operative Pain Following Lumbar Surgery

NCT02416973

Lumbar Surgery

COMPLETED NA

Multi-modal Imaging of Myofascial Pain - Phase 2

NCT07322445

Myofascial Pain

RECRUITING NA

Evaluation of a Novel Class of Objective Myofascial Pain Assessments

NCT05793086

Myofascial Pain Trigger Point Pain, Myofascial

ACTIVE_NOT_RECRUITING

The Effect of Pulsed Electromagnetic Field Therapy on Patients With Low Back Pain

NCT03053375

Low Back Pain

UNKNOWN NA

Multi-modal Imaging of Myofascial Pain

NCT06036524

Myofascial Pain

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open-label, non-controlled trial in subjects with various pain etiologies at multiple centers in the US. Eligible subjects will include those ≥ 22 years of age that have been deemed appropriate for treatment with Provant by the study investigator (prescriber). Subjects will treat based on the treatment prescribed (location, frequency, duration) by the study investigator.

Data from assessments administered as part of standard of practice will be obtained at baseline and, at a minimum, at the end of treatment. If the investigator administers additional assessments during the course of treatment, the data will be collected.

Safety will be assessed during office visits and through review of AE reports and concomitant treatments and medications. All concomitant drug or non-drug treatments used during the study will be recorded.

Information collected in the study will be entered into a registry database.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active Treatment Arm

Treatment with Provant Therapy System

Group Type EXPERIMENTAL

Provant Therapy System

Intervention Type DEVICE

Treatment with the Provant Therapy System

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Provant Therapy System

Treatment with the Provant Therapy System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject age is greater than or equal to 22 years.
2. Subject has pain (chronic or acute) and/or edema that the prescriber deems treatment with Provant is warranted.
3. Subject is willing and able to give written informed consent.
4. Female subjects must be post-menopausal, surgically sterile, abstinent, or practicing (or agree to practice) an effective method of birth control if they are sexually active for the duration of the study. (Effective methods of birth control include prescription hormonal contraceptives, intrauterine devices, double-barrier methods, and/or male partner sterilization).

Exclusion Criteria

1. Subject requires or anticipates the need for surgery of any type during the duration of treatment.
2. Subject has received any investigational drug or device within 30 days or 5 half-lives of the drug, whichever is longer, prior to the Screening Visit or is enrolled in another clinical trial.
3. Subject has used systemic corticosteroids within 2 months of the Screening Visit.
4. Subject has a history of a solid tumor that is not in complete remission for greater than 2 years other than successfully treated non-metastatic basal cell or squamous cell carcinomas of the skin in the treatment area.
5. Subject has a history of blood cancer (e.g., leukemia, lymphoma, multiple myeloma).
6. Subject has a serious psychosocial co-morbidity.
7. Subject has a history of drug or alcohol abuse within one year prior to the Screening Visit.
8. Subject has an implanted pacemaker, defibrillator, neurostimulator, spinal cord stimulator, bone stimulator, cochlear implant, or other implanted device with an implanted metal lead(s).
9. Subject is currently pregnant or planning on becoming pregnant during the treatment period.
10. Subject has been previously treated with the Provant Therapy System.
11. Subject is unwilling or unable to follow study instructions, or comply with the treatment regimen and study visits.

Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No